The CXCR4 inhibitor treatment decreased the KR-induced gene expression profile and breast cancer progression when compared to that of the KR alone group, suggesting that mTOR pathway activation is relevant for DPP-4 inhibitor-mediated breast cancer progression. The gene discussed is DPP4; the disease is breast carcinoma.